Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: GENFIT

Market Cap 461M 535M 424M 398M 748M 50.56B 755M 5.02B 1.96B 24.76B 2.01B 1.97B 85.68B P/E Ratio 2025
-3.06x
P/E Ratio 2026 * 48.7x
Enterprise Value 406M 471M 374M 351M 659M 44.56B 666M 4.42B 1.73B 21.82B 1.77B 1.73B 75.51B EV / Sales 2025
2.34x
EV / Sales 2026 * 4.35x
Free-Float
86.88%
Yield 2025 *
-
Yield 2026 * -
Manager TitleAgeSince
Chief Executive Officer 58 2019-09-15
Director of Finance/CFO 52 2021-04-21
Chief Tech/Sci/R&D Officer - 2025-11-26
Director TitleAgeSince
Chairman 70 2017-06-15
Director/Board Member 54 1999-09-14
Director/Board Member 58 2017-06-15
Change 5-day change 1-year change 3-year change Capi.($)
+0.96%+1.16%-12.70%-12.33% 43.03B
+3.84%+7.55%+301.57%+535.25% 32.71B
-1.87%-3.66%+11.13%-18.36% 30.29B
+0.84%-1.81%+0.56%+32.27% 29.4B
+1.16%+2.10%+14.27%+22.05% 25.08B
+2.33%+8.47% - - 13.54B
-0.17%+1.69%+54.70%+111.06% 13.35B
-1.09%-2.37%+5.07%+5.25% 12.97B
+0.66%+0.12%+108.94%+76.61% 12.11B
Average +0.60%+0.70%+60.44%+93.98% 23.61B
Weighted average by Cap. +0.72%+0.75%+61.05%+102.56%

Financials

2025 2026 *
Net sales 66.82M 77.52M 61.49M 57.69M 108M 7.33B 109M 727M 284M 3.59B 291M 285M 12.41B 95.2M 110M 87.61M 82.19M 154M 10.44B 156M 1.04B 405M 5.11B 414M 406M 17.69B
Net income -8.3M -9.63M -7.64M -7.17M -13.46M -910M -13.6M -90.33M -35.28M -446M -36.15M -35.38M -1.54B 18.31M 21.24M 16.85M 15.81M 29.69M 2.01B 29.99M 199M 77.8M 983M 79.7M 78.02M 3.4B
Net Debt -54.72M -63.49M -50.36M -47.24M -88.75M -6B -89.63M -595M -233M -2.94B -238M -233M -10.17B -46.87M -54.38M -43.13M -40.46M -76.01M -5.14B -76.77M -510M -199M -2.52B -204M -200M -8.71B
Logo GENFIT
GENFIT is a biopharmaceutical company in late-stage development focused on the discovery and development of innovative therapeutic and diagnostic solutions in the field of liver diseases, particularly of metabolic origin, where unmet medical needs are considerable, in particular due to a lack of approved treatments. GENFIT is a leading innovator in the field of nuclear receptor-based drug discovery with a rich history and a solid scientific heritage spanning nearly two decades. The company has offices in Lille, Paris, Zurich and Cambridge, MA (USA).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!